synthesized from 3 g of total RNA using random hexamers (Promega Corporation, Madison, 11 WI, USA). Amplification of cDNA by PCR was performed in a total reaction volume of 30 12 L containing 0.5 units of Taq polymerase (TaKaRa Bio Inc., Otsu, Shiga, Japan) and 10 13 picomoles of primers specific for human IL-8, IRAK-M, TOLLIP, A20, SOCS-1, CD36, 14 CD14, MD2, TLR2, TLR4, and β-actin. The sequences of primers specific for the target 15 genes are given in Table 1 . Using a 2% agarose gel, amplified PCR products (35 and 28 16 cycles for target genes and -actin, respectively) were separated and then visualized by 17 staining with ethidium bromide. The data were analyzed with an image analyzer (Bio-Capt 18 cytometric data were analyzed with FlowJo software (Tree Star, San Carlos, CA, USA). 1 2
Western blot analysis 3
Western blotting was performed as described previously with minor modification (21). For 4 analysis of phosphorylation of MAPKs, including p38 kinase, JNK, and ERK, PDL cells (5 5 mL at 2 × 10 5 cells/mL) were plated in a 100-mm tissue culture dish and cultured overnight. 6
The cells were then pretreated with Ef.LTA at various doses for 1 h followed by stimulation 7 with 0.1 g/mL of Aa.LPS for an additional 1 h. For analysis of IRAK-M activation, the cells 8 were pretreated with Ef.LTA at various doses for 1 h followed by stimulation with 0.1 g/mL 9 of Aa.LPS for an additional 3 h. The cells were then lysed with RIPA buffer (Cell Signaling 10 Technology), and cell lysates were collected by centrifugation. A 10% SDS-PAGE gel was 11 used to separate the lysates, which were then electrotransferred to a PVDF membrane 12 (Millipore, Bedford, MA, USA) using a tank transfer system (Bio-Rad, Hercules, CA, USA). 13
The membrane was then blocked with 5% skim milk in TBST (Cell Signaling Technology) at 14 room temperature for 1 h and incubated with primary antibodies specific for IRAK-M, p38 15 kinase, phospho-p38 kinase (p-p38), JNK, phospho-JNK (p-JNK), ERK, or phospho-ERK (p-16 ERK) MAPK at 4ºC overnight. The membrane was then washed with TBST and incubated1 (LAS-1000 plus, Fuji, Tokyo, Japan) using an image analysis program (MultiGauge, Fuji) and 2 expressed as the ratio of phosphorylated to non-phosphorylated protein for each indicated 3
MAPK. 4 5
Transfection and luciferase reporter gene assay 6
The IL-8 promoter/pGL3 reporter construct and the three mutant promoter reporter constructs 7 (IL-8 promoter with site-specific mutations for NF-κB, AP-1, or C/EBP transcription factor-8 binding sites/pGL3) were kindly provided by Dr. Myung Hyun Sohn at Yonsei University, 9
Korea (22). The NF-B and AP-1 reporter constructs were purchased from Clontech 10 (Mountain View, CA, USA). The C/EBP reporter construct was obtained from Stratagene (La 11 Jolla, CA, USA). PDL cells were plated at 2 × 10 5 cells/mL in a 6-well plate and cultured for 12 24 h. The cells were then transiently transfected with the aforementioned constructs together 13 with a Renilla luciferase expression plasmid (pRL-TK; Promega) in serum-and antibiotic-14 free DMEM with TransFectin lipid reagent (Bio-Rad) for 24 h. After transfection, the cells 15 were pretreated with Ef.LTA at various doses for 1 h followed by stimulation with 0.1 g/mL 16 of Aa.LPS for an additional 24 h. At the end of the stimulation, the cells were lysed with Glo 17 Lysis Buffer (Promega) and the luciferase activity in the cytoplasmic extracts was assayed 18 using a luminometer (Victor 3, Waltham, MA, USA). The data were expressed as relativeluciferase activity, where firefly luciferase activity (expressed from the IL-8 promoter 1 construct or the reporter constructs for each transcription factor) was normalized to Renilla 2 luciferase activity in each same cytoplasmic extract to correct for differences in transfection 3 efficiencies. 
Statistical analysis
All experiments were conducted at least three times, and the mean value + standard deviation 1 (S.D.) was determined for each treatment group in a given experiment. Treatment groups 2 were compared with the appropriate control groups, and statistical significance was 3 determined using Student's t-test. Differences were considered significant when P < 0.05. Since previous studies have reported that Ef.LTA is recognized by CD14, CD36, and TLR2, 6 whereas Aa.LPS is recognized by CD14 and the TLR4/MD2 complex (24-26), we examined 7 the mRNA expression of the genes for those proteins in PDL cells by RT-PCR analysis using 8 the human monocytic cell-line THP-1 as a control. The expression level of all mRNA, except 9 that for MD2, was relatively lower in PDL cells than in THP-1 cells (Fig. 3A) . However, 10 upon exposure to Aa.LPS, the mRNA expression of TLR4 and CD36 was enhanced in PDL 11 cells, but no change was observed in mRNA expression of TLR2, CD14 and MD2 in PDL 12 cells (Fig. 3B) . Next, to examine whether Ef.LTA could inhibit Aa.LPS-induced TLR4 13 activation, CHO/CD14/TLR4 cells were pretreated with various doses of Ef.LTA for 1 h and 14 subsequently stimulated with 0.1 g/mL of Aa.LPS for 20 h. As shown in Fig. 3C and JNK, are involved in the regulation of IL-8 mRNA expression at the transcriptional and 7 post-transcriptional levels (27,28). Therefore, we examined whether Ef.LTA inhibits 8 phosphorylation of MAPKs induced by Aa.LPS using Western blot analysis. When PDL cells 9
were pretreated with Ef.LTA at 7.5 -30 g/mL for 1 h followed by stimulation with 0.1 10 g/mL of Aa.LPS for an additional 1 h, the Aa.LPS-induced phosphorylation of all MAPKs 11 was decreased (Fig. 4A, B , and C). However, no significant change was observed in the 12 phosphorylation of JNK, p38 kinase, and ERK MAPKs in PDL cells treated with Ef.LTA 13 alone (data not shown). factors is regulated by the aforementioned MAPKs (30). Therefore, we performed a reportergene assay using a luciferase reporter whose expression is under the control of an intact IL-8 1 promoter region. The Aa.LPS-elevated IL-8 promoter activity was suppressed by Ef.LTA in a 2 dose-dependent manner (Fig. 5A) Aa.LPS-stimulated PDL cells, we examined changes in the expression of these intracellular 17 negative regulators of TLR signaling pathways. When PDL cells were pretreated with Ef.LTA 18 at 7.5 -30 g/mL for 1 h followed by stimulation with 0.1 g/mL of Aa.LPS for an additional3 h, only IRAK-M mRNA expression was found to be enhanced by Ef.LTA in a dose-1 dependent manner (Fig. 6A) . Moreover, we found that IRAK-M production was elevated at 2 the protein level by Ef.LTA in the presence of Aa.LPS (Fig. 6B) . Furthermore, in order to 3 examine whether Ef.LTA enhances IRAK-M expression through TLR2, PDL cells were 4 transfected with siRNA against TLR2 followed by stimulation with Aa.LPS in the presence of 5
Ef.LTA. TLR2 siRNA completely silenced TLR2 gene and reduced IRAK-M expression in 6 the presence of Ef.LTA and Aa.LPS (Fig. 6C) suggesting that IRAK-M expression is 7 regulated by Ef.LTA-mediated TLR2 signaling. To confirm that the decreased IL-8 8 production induced by Ef.LTA was mediated by increased IRAK-M activation, we 9 investigated the effect of siRNA for IRAK-M in PDL cells. As shown in Fig. 6D (left panel) , 10 IRAK-M mRNA expression was completely abolished by transfection with IRAK-M siRNA. 11
When cells transfected with IRAK-M siRNA or scrambled control siRNA were pretreated 12 with various concentrations of Ef.LTA followed by stimulation with Aa.LPS, IL-8 production 13 was restored (Fig. 6D, right panel) . 
